Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 9, 2014, Pages

  Tardy, Magdolna ^a   Dold, Markus ^a   Engel, Rolf R ^b   Leucht, Stefan ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; FLUPENTIXOL; NEUROLEPTIC AGENT;

ADVERSE OUTCOME; ANTICHOLINERGIC SYNDROME; ASSESSMENT OF HUMANS; BRIEF PSYCHIATRIC RATING SCALE; CARDIOVASCULAR DISEASE; DIZZINESS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DYSTONIA; HUMAN; HYPERSALIVATION; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT EMERGENT SYMPTOM RATING SCALE; TREMOR; UNSTEADY GAIT; XEROSTOMIA; AKATHISIA, DRUG-INDUCED; CHEMICALLY INDUCED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; FLUPENTHIXOL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; XEROSTOMIA;

EID: 84942805235     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009227.pub2     Document Type: Review

References (58)

1. Liu QZ, Wang LH, Han YF, Zhou CL, Wang LH. A comparative study of fluanxol and chlorpromazine used for schizophrenia. Journal of Taishan Medical College 2000;21(2):117-21.
2. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 1986;148(2):120-7.
3. Johnstone EC, Crow TJ, Johnson AL, MacMillan JF. The Northwick Park study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. British Journal of Psychiatry 1986;148(2):115-20.
4. Johnstone EC, Owens DGC. Does early treatment have an effect on outcome?. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997.
5. MacMillan JF, Crow TJ, Johnson AL, Johnstone EC. Short-term outcome in trial entrants and trial eligible patients. British Journal of Psychiatry 1986;148(2):128-33.
6. Ishimaru T, Kubo S, Ishikawa H. Clinical evaluation on effect of flupentixol, a neuroleptic drug, on schizophrenia by double-blind controlled trial. Seishin Igaku (Clinical Psychiatry) 1971;13(7):739-47.
7. Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978;1(8069):848-51.
8. Joseph MH, Baker HF, Johnstone EC, Crow TJ. 3-methoxy-4-hydroxyphenylglycol excretion in acutely schizophrenic patients during a controlled clinical trial of the isomers of flupenthixol. Psychopharmacology 1979;64(1):35-40.
9. Adams CE, Coutinho E, Davis JM. Cochrane Schizophrenia Group. The Cochrane Library 2008; Vol. 4.
10. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic drug equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biological Psychiatry 2010;67:255-62.
11. American Psychistric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR). Washington DC: American Psychistric Association, 2000.
12. Berger M. Psychische Erkrankungen. Klinik und Therapie. 2nd Edition. München: Urban & Fischer, 2003.
13. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
14. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al.The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
15. Campbell M, Grimshaw J, Steen N. Sample size calculations for cluster randomised trials. Changing Professional Practice in Europe Group (EU BIOMED II Concerted Action). Journal of Health Services Research and Policy 2000;5:12-6.
16. Carpenter WT, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
17. Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. American Journal of Psychiatry 1975;132(12):1237-45.
18. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. Comprehensive Textbook of Psychiatry. Baltimore, MD: Williams and Wilkins, 1989.
19. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. Cape Town, 2000.
20. Der-Simonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
21. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
22. Dold M, Li C, Tardy M, Leucht S. Haloperidol versus first generation antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009831]
23. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
24. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
25. Falkai P, Wobrock T, Lieberman J. World Federation of Societies of Biological Psychiatry (WFSBP) - Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World Journal of Biological Psychiatry 2005;6:132-91.
26. Gaebel W, Falkai P, Weinmann S. Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff, 2006.
27. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
28. Haase HJ. Dosierung der Neuroleptika. Ein Leitfaden Für Klinik Und Praxis Unter Besonderer Berücksichtigung Psychotisch Kranker. Erlangen: Perimed Fachbuch-Verlagsgesellschaft, 1983.
29. Hartung B, Wada M, Laux G, Leucht S. Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD003443.pub2]
30. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
31. Jones PB, Barnes TRE, Davies L. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia - cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry 2006;63:1079-86.
32. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi-Health Systems, 1986.
33. Kirk L, Jørgensen A. Concentrations of Cis(Z)-flupentixol in maternal serum, amniotic fluid, umbilical cord serum, and milk. Psychopharmacology 1980;72:107-8.
34. Klein DF, Davis JM. Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore: Williams and Wilkins, 1969.
35. Lehman AF, Lieberman JA, Dixon LB. Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 2004;161:1-56.
36. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59:1001-5.
37. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
38. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
39. Leucht S, Corves C, Arbter D, Engel R, Li C, Davis JM. A meta-analysis comparing second-generation and first-generation antipsychotics for schizophrenia. Lancet 2009;373:31-41.
40. Lieberman JA, Stroup TS, McEvoy JP. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209-23.
41. Lohse MJ, Lorenzen A, Müller-Oerlinghausen B. Psychotropic Drugs [Psychopharmaka]. In: Schwabe U, Pfaffrath D editor(s). Arzneimittelverordnungsreport. Springer, Berlin, 2005:820-64.
42. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
43. Marvaha S, Johnson S. Schizophrenia and employment: a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337-49.
44. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al.CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
45. National Institute of Mental Health. Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacological Bulletin 1985;21(4):714-1124.
46. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-12.
47. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
48. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975;188:1217-9.
49. Shen X, Xia J, Adams Clive E. Flupenthixol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012, issue 11. [DOI: 10.1002/14651858.CD009777.pub2]
50. Simpson EN, Angus JWF. A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica Supplementum 1970;212:11-9.
51. Sultana A, Reilly J, Fenton M. Thioridazine for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD001944]
52. Tardy M, Leucht S, Potapov A, Engel R, Huhn M, Kissing W. Perphenazine versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD009369]
53. Tardy M, Leucht S, Potapov A, Engel R, Huhn M, Kissing W. Fluphenazine versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD009230]
54. Tardy M, Leucht S, Potapov A, Engel R, Dold M, Kissling W. Trifluoperazine versus low-potency first generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD009396]
55. Tardy M, Leucht S, Potapov A, Kissing W, Engel R, Huhn M, et al.Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD009268]
56. Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, et al.EU-PSI project. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. Journal of Clinical Epidemiology 2004;57(11):1124-30.
57. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153-5.
58. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.The Leeds Outcomes Stakeholders Survey (LOSS) Study. Proceedings of the 15th Cochrane Colloquium;Oct 23-27; Sao Paulo. 2007.